{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:31Z","timestamp":1793761051551,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,14]],"date-time":"2027-05-14T00:00:00Z","timestamp":1810252800000},"content-version":"am","delay-in-days":590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013352","name":"Tow Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016982","name":"Rising Tide Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems","doi-asserted-by":"publisher","award":["P30 CA240139"],"award-info":[{"award-number":["P30 CA240139"]}],"id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:00:47Z","timestamp":1773457247000},"page":"400-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted immunoPET imaging of multiple myeloma"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-0113","authenticated-orcid":false,"given":"Gary A.","family":"Ulaner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0001","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla","year":"2015","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.005_bib0003","first-page":"930","article-title":"Non-secretory myeloma: one, two, or more entities?","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Oncol (Willist Park)"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0004","first-page":"81","article-title":"Non-secretory multiple myeloma relapsing as extramedullary liver plasmacytomas","volume":"20","author":"Lopes da Silva","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.005_bib0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.005_bib0006","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0007","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM guidelines on the use of [(18)F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.005_bib0009","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \"early myeloma\"","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.005_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","article-title":"MGUS and smoldering multiple myeloma: diagnosis and epidemiology","volume":"169","author":"Mateos","year":"2016","journal-title":"Cancer Treat Res"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.03.005_bib0012","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","article-title":"The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications","volume":"23","author":"Anderson","year":"2017","journal-title":"Clin cancer res: off j Am Assoc Cancer Res"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.03.005_bib0013","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","article-title":"MRD testing in multiple myeloma: the main future driver for modern tailored treatment","volume":"55","author":"Landgren","year":"2018","journal-title":"Semin Hematol"},{"issue":"5517","key":"10.1053\/j.seminhematol.2026.03.005_bib0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0017","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted immuno-PET of Multiple myeloma: from xenograft models to first-in-Human imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.005_bib0018","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","article-title":"Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-Trastuzumab PET\/CT","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0019","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-Human Human epidermal growth factor receptor 2-targeted imaging using (89)Zr-Pertuzumab PET\/CT: dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.123.266392","article-title":"First-in-Human evaluation of site-specifically labeled (89)Zr-Pertuzumab in patients with HER2-positive breast cancer","volume":"65","author":"Yeh","year":"2024","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0021","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp Mol Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0022","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1158\/0008-5472.CAN-06-2887","article-title":"Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors","volume":"67","author":"Orlova","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0023","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.005_bib0024","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2967\/jnumed.122.264183","article-title":"Choice is good at times: the emergence of [(64)Cu]Cu-DOTATATE-based somatostatin receptor imaging in the era of [(68)Ga]Ga-DOTATATE","volume":"63","author":"Jha","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7150\/thno.39089","article-title":"The Influence of Glycans-Specific Bioconjugation on the Fc\u03b3RI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab","volume":"10","author":"Vivier","year":"2020","journal-title":"Theranostics"},{"issue":"Suppl 2","key":"10.1053\/j.seminhematol.2026.03.005_bib0026","doi-asserted-by":"crossref","first-page":"105s","DOI":"10.2967\/jnumed.120.250191","article-title":"(18)F-FDG radiosynthesis: a landmark in the history of PET","volume":"61","author":"Fowler","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminhematol.2026.03.005_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography","volume":"76","author":"Sanchez-Crespo","year":"2013","journal-title":"Appl Radiat Isot"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0028","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.005_bib0029","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64-labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2967\/jnumed.124.269393","article-title":"CD38-Targeted (89)Zr-DFO-Daratumumab PET of myeloma: immuno-PET impacting clinical care CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"66","author":"Ulaner","year":"2025","journal-title":"J Nucl Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.03.005_bib0031","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","article-title":"Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab","volume":"4","author":"Krishnan","year":"2020","journal-title":"Blood Adv"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.03.005_bib0032","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1021\/acsomega.3c00624","article-title":"(89)Zr-DFO-Isatuximab for CD38-targeted ImmunoPET imaging of Multiple myeloma and lymphomas","volume":"8","author":"Alvarez","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40658-021-00352-z","article-title":"Improved image reconstruction of (89)Zr-immunoPET studies using a bayesian penalized likelihood reconstruction algorithm","volume":"8","author":"Kirchner","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.03.005_bib0034","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","article-title":"ImmunoPET imaging of multiple myeloma with [(68)Ga]Ga-NOTA-Nb1053","volume":"48","author":"Wang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.03.005_bib0035","article-title":"CD38-Specific gallium-68 labeled peptide radiotracer enables pharmacodynamic monitoring in multiple myeloma with PET","volume":"11","author":"Sharma","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.005_bib0036","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s11307-024-01901-5","article-title":"Development of new CD38 targeted peptides for cancer imaging","volume":"26","author":"Zheleznyak","year":"2024","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.005_bib0037","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acs.bioconjchem.4c00497","article-title":"Pharmacokinetic positron emission tomography imaging of an optimized CD38-targeted (68)Ga-labeled peptide in multiple myeloma: a pilot study","volume":"35","author":"Yang","year":"2024","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0038","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies","volume":"52","author":"Huang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0039","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-23-2130","article-title":"CD46-Targeted theranostics for PET and 225Ac-radiopharmaceutical therapy of multiple myeloma","volume":"30","author":"Wadhwa","year":"2024","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0041","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13277-012-0362-y","article-title":"Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients","volume":"33","author":"Rousseau","year":"2012","journal-title":"Tumour Biol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.005_bib0042","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.18632\/oncotarget.23886","article-title":"Comparison of immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma","volume":"9","author":"Bailly","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.005_bib0043","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/ijms20102564","article-title":"What is the best radionuclide for immuno-PET of multiple myeloma? A comparison study between (89)Zr- and (64)Cu-labeled anti-CD138 in a preclinical syngeneic model","volume":"20","author":"Bailly","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0044","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00259-020-05002-7","article-title":"Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET","volume":"48","author":"Chomet","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.005_bib0045","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/pharmaceutics15071817","volume":"15","author":"M\u00e9tivier","year":"2023","journal-title":"Pharmaceutics"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.03.005_bib0046","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1021\/acs.jmedchem.4c00759","article-title":"Development of a novel peptide-based PET tracer [(68)Ga]Ga-DOTA-BP1 for BCMA detection in multiple myeloma","volume":"67","author":"Song","year":"2024","journal-title":"J Med Chem"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0047","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00259-024-06907-3","article-title":"Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: applications in PET imaging of multiple myeloma","volume":"52","author":"Ma","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.03.005_bib0048","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1021\/acs.jmedchem.5c01010","article-title":"Development and preclinical validation of a novel (89)Zr-labeled BCMA-targeting antibody for ImmunoPET imaging: application in multiple myeloma models and first-In-nonhuman-primates","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0049","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-025-01758-3","article-title":"B-cell maturation antigen targeted PET\/CT imaging in multiple myeloma: a first-in-human study","volume":"18","author":"Gu","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00259-020-05097-y","article-title":"Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma","volume":"48","author":"Ghai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055841","article-title":"Very late antigen-4 (\u03b1(4)\u03b2(1) Integrin) targeted PET imaging of multiple myeloma","volume":"8","author":"Soodgupta","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.005_bib0052","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2967\/jnumed.115.164624","article-title":"Ex vivo and In vivo evaluation of overexpressed VLA-4 in multiple myeloma using LLP2A imaging agents","volume":"57","author":"Soodgupta","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0053","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13550-021-00840-4","volume":"11","author":"Ghai","year":"2021","journal-title":"EJNMMI Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0054","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11307-021-01666-1","article-title":"PET imaging of VLA-4 in a new BRAF(V600E) mouse model of melanoma","volume":"24","author":"Bellavia","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.122.264349","article-title":"First-in-humans evaluation of safety and dosimetry of (64)Cu-LLP2A for PET imaging","volume":"64","author":"Laforest","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0056","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1535-7163.MCT-24-0370","article-title":"Evaluation of VLA-4 (Integrin \u03b14\u03b21) as a shared target for radiopharmaceutical therapy across solid tumors","volume":"24","author":"Reyes-Gonz\u00e1lez","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0057","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0058","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.005_bib0059","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.005_bib0060","first-page":"1687","article-title":"Imaging of C-X-C Motif Chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-Pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"issue":"1136","key":"10.1053\/j.seminhematol.2026.03.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-Pentixafor PET\/CT: comparison with (18)F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.005_bib0062","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/RLU.0000000000005426","article-title":"CXCR4-Targeted PET imaging in hematologic malignancies: a systematic review and meta-analysis","volume":"50","author":"Chavoshi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0063","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1097\/RLU.0000000000005731","article-title":"68 Ga-Pentixafor PET\/CT-based response evaluation and its prognostic value in multiple myeloma: comparison with IMWG and 18 F-FDG-based response","volume":"50","author":"Kaur","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0064","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/RLU.0000000000005813","article-title":"Myeloablative radioligand therapy targeting C-X-C Motif Chemokine receptor 4 in advanced multiple myeloma","volume":"50","author":"Dreher","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.005_bib0065","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-024-07025-w","article-title":"Selective PET imaging of CXCR4 using the Al(18)F-labeled antagonist LY2510924","volume":"52","author":"Spahn","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.03.005_bib0066","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.2967\/jnumed.115.157909","article-title":"Molecular imaging of biomarkers in breast cancer","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.005_bib0067","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","article-title":"A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies","volume":"74","author":"Green","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.005_bib0068","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.18632\/oncotarget.2986","article-title":"alpha-radioimmunotherapy with (2)(1)(3)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma","volume":"6","author":"Teiluf","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.005_bib0069","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1021\/acs.molpharmaceut.7b00298","article-title":"CD38 as a PET imaging target in lung cancer","volume":"14","author":"Ehlerding","year":"2017","journal-title":"Mol Pharm"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.005_bib0070","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","article-title":"ImmunoPET imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab","volume":"45","author":"Kang","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0071","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cyto.2013.02.023","article-title":"Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients","volume":"62","author":"Pavon","year":"2013","journal-title":"Cytokine"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.005_bib0072","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/cei.12268","article-title":"CD38 and E2F transcription factor 2 have uniquely increased expression in rheumatoid arthritis synovial tissues","volume":"176","author":"Chang","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.03.005_bib0073","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:07:23Z","timestamp":1778728043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000181"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted immunoPET imaging of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}